HIV mutation literature information.


  Effects of drug resistance on viral load in patients failing antiretroviral therapy.
 PMID: 16555280       2006       Journal of medical virology
Abstract: Certain reverse transcriptase mutations such as M184V/I, K70R, V108I, and protease mutations such as L33FIV, M84V, and M36I were associated with reduced viral load.


  Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection.
 PMID: 12843744       2003       Journal of acquired immune deficiency syndromes (1999)
Abstract: The mutations T69N and V75M in reverse transcriptase and L10F, K20I, L33I, and N88S in protease were seen more frequently in patients infected with CRF01_AE than in patients with subtype B.


  Comparative study of some energetic and steric parameters of the wild type and mutants HIV-1 protease: a way to explain the viral resistance.
 PMID: 12169210       2002       Journal of cellular and molecular medicine
Abstract: Because, in vivo, the HIV-1 PR ( HIV-1 protease) present a high mutation rate we performed a comparative study of the energetic behaviors of the wild type HIV-1 PR and four type of mutants: Val82/Asn; Val82/Asp; Gln7/Lys, Leu33/Ile, Leu63/Ile; Ala71/Thr, Val82/Ala.


  Drug resistance mutations can effect dimer stability of HIV-1 protease at neutral pH.
 PMID: 10452615       1999       Protein science
Abstract: An autolysis-resistant mutant, Q7K/L33I/L63I, was used to facilitate sedimentation equilibrium studies at neutral pH where the wild-type enzyme is typically unstable in the absence of bound inhibitor.


  Conformational stability and catalytic activity of HIV-1 protease are both enhanced at high salt concentration.
 PMID: 8621402       1996       The Journal of biological chemistry
Abstract: The structural basis of this effect has been explored by several independent methods by using both the wild-type enzyme and its triple mutant (Q7K/L33I/L63I) (Mildner, A.


  The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties.
 PMID: 8068616       1994       Biochemistry
Abstract: Q7K/L33I/L63I should find useful application as a stable surrogate of the HIV-1 protease.
Abstract: However, one of the mutant proteases, Q7K/L33I/L63I, was highly resistant to autolysis, while retaining the physical properties, specificity, and susceptibility to inhibition of the wild-type enzyme.



Browser Board

 Co-occurred Entities




   Filtrator